Fibrin and Cancer

• References

• 1 Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris. London: New Sydenham Society; 1865 3. 94
• 2 Billroth T. Lectures on Surgical Pathology and Therapeutics (translated from ed. 8). London: The New Syndeham Society; 1878
• 3 Sack Jr GH, Levin J, Bell W. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathologic, and therapeutic features. Medicine 1977; 56: 1-27
• 4 Donati MB, Poggi A, Semeraro N. Coagulation and malignancy. In: Recent Advances in Blood Coagulation (vol.3). Poller L. (ed) New York: Livingston; 1981: 375-391
• 5 Dvorak HF. Tumors: Wounds that do not heal. N Engl J Med 1986; 315: 1650-1659
• 6 Rickles FR, Edwards RL. Activation of blood coagulation in patients with cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31
• 7 Zacharski LR, Henderson WG, Rickles FR, Forman WG, Cornell CJ, Harrower HW, Johnson RO. Rationale und experimental design for the VA Cooperative Study of anticoagulation (warfarin) in the treatment of cancer. Cancer 1979; 44: 732-741
• 8 Zacharski LR, Henderson WG, Rickles FR, Forman WG, Van Eeckhout JP, Cornell CJ, Forcier RJ, Martin JF. Rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Am J Clin Oncol 1982; 5: 593-609
• 9 Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumor tissue: Implications for cancer therapy. Blood Coag Fibrinolys 1990; 1: 71-78
• 10 Zacharski LR, Costantini V, Wojtukiewicz MZ, Memoli VA, Kudryk BJ. Anticoagulants as cancer therapy. Semin Oncol 1990; 17: 217-227
• 11 Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Hemostas Thromb 1992; 18: 104-116
• 12 O’Meara RAQ. Coagulative properties of cancers. Irish J Med Sci 1958; 394: 474-479
• 13 Day ED, Planinsek JA, Pressman D. Localization in vivo of radioiodinated anti-rat fibrin antibodies and radioiodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors. J Natl Cancer Inst 1959; 22: 413-426
• 14 Spar IL, Bale WF, Marrack D, Dewey WC, McCardle RJ, Harper PV. ¹³¹I-labeled antibodies to human fibrinogen: Diagnostic studies and therapeutic trials. Cancer 1967; 20: 865-870
• 15 Laki K, Yancey ST. Fibrinogen and the tumor problem. In: Fibrinogen. Laki K. (ed) Marcel Dekker; New York: 1968: 359-367
• 16 Hiramoto R, Yagi Y, Pressman D. Immunohistochemical studies of antibodies in anti-Murphy lymphosarcoma sera. Cancer Res 1959; 19: 874-879
• 17 Hiramoto R, Bernecky J, Jurandowski J, Pressman D. Fibrin in human tumors. Cancer Res 1960; 20: 592-593
• 18 Bini A, Mea-Tejada R, Fenoglio Jr JJ, Kudryk B, Kaplan KL. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies. Lab Invest 1989; 60: 814-821
• 19 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. A monoclonal antibody with ability to distinguish between NH₂-terminal fragments derived from fibrinogen and fibrin. Mol Immunol 1983; 20: 1191-1200
• 20 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21: 89-94
• 21 Kudryk BJ, Grossman ZD, McAfee JG, Rosebrough SE. Monoclonal antibodies as probes for fibrin(ogen) proteolysis. In: Monoclonal Antibodies in Immunoscintigraphy. Chatal JF. (ed) CRC Press; Boca Raton, FL: 1988: 365-398
• 22 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132
• 23 Harris NL, Dvorak AM, Smith J, Dvorak HE. Fibrin deposits in Hodgkin’s disease. Am J Pathol 1982; 108: 119-129
• 24 Zacharski LR, Schned A, Sorenson GD. Occurrence of fibrin and tissue factor antigen in small cell carcinma of the lung. Cancer Res 1983; 43: 3963-3968
• 25 Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH. Fibrin-gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs: Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 1979; 62: 1459-1472
• 26 Zacharski LR, Memoli VA, Rousseau SM. Cancer-coagulation interaction in situ in renal cell carcinoma. Blood 1986; 68: 394-399
• 27 Rickles FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastatic agents. I. The role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemostas 1988; 14: 88-94
• 28 Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and non-malignant lymphoid tissue. J Lab Clin Med 1992; 119: 124-131
• 29 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-485
• 30 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Malignant melanoma: Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-521
• 31 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Moritz TE, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991; 67: 1377-1383
• 32 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-582
• 33 Brown LF, Asch B, Harvey VS, Buchinski B, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer Res 1988; 48: 1920-1925
• 34 Zacharski LR, Donati MB. Registry of clincial trials of antithrombotic drugs in cancer. Thromb Haemostas 1989; 61: 526-528
• 35 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Headley E, Kim S-H, O-Dell R, Tornyos K, Kwaan HC. Effect of sodium warfarin on survival in small cell carcinoma of the lung. J Am Med Assoc 1981; 245: 831-835
• 36 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E, Kim S-H, O-Donnell JF, O’Dell R, Tornyos K. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of the VA Cooperative Study 75. Cancer 1984; 53: 2046-2052
• 37 Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL, Green MR. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 993-1002
• 38 Lebeau B, Chastang CL, Brechot JM. Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer (SCLC). Lung Cancer 1991; (Suppl. 07) 129
• 39 Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: original and biological significance. Cancer Metast Rev 1983; 2: 41-73
• 40 Zacharski LR, Dunwiddie C, Nutt EM, Hunt J, Memoli VA. Cellular localization of activated factor X by a Xa-specific probe. Thromb Heamostas 1991; 65: 545-548
• 41 Pineo GF, Brain MC, Gallus AS, Hirsh J, Hatton MWC, Regoeczi E. Tumors, mucus production, and hypercoagulability. Ann NY Acad Sci 1974; 230: 262-270
• 42 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Indirect activation of coagulation in colon cancer. Thromb Haemostas 1989; 62: 1062-1066
• 43 Adany R, Szegedi A, Nemes Z, Muszbek L. Extravasal fibrin stabilization by factor XIII in lymph nodes with Hodgkin’s disease. Thromb Haemostas 1987; 58: 235
• 44 Ornstein D, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stumo DC. Coexistent macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer 1991; 68: 1061-1067
• 45 Mosesson MW. Fibrinogen heterogeneity. Ann N Y Acad Sci 1983; 408: 164-179
• 46 Folk JE, Finlayson JS. The ε(γglutamyl) lysine crosslink and the catalytic role of transglutaminase. Adv Protein Chem 1977; 31: 1-33
• 47 McDonagh J. Plasma fibronectin: Structure and Function. Marcel Dekker. New York: 1985
• 48 Dvorak HF, Dickersin GR, Dvorak AM, Manseau EJ, Pyne K. Human breast carcinoma: fibrin deposits and desmoplasia, inflammatory cell type and distribution, microvasculature and infarction. J Natl Cancer Inst 1981; 67: 335-345
• 49 Zacharski LR, Memoli VA, Rousseau SM, Kisiel W. Coagulation-cancer interaction in situ in small cell carcinoma of the lung. Cancer 1987; 60: 2675-2681
• 50 Zacharski LR, Memoli VA, Rousseau SM. Thrombin-specific sites of fibrinogen in small cell carcinoma of the lung. Cancer 1988; 62: 299-302
• 51 Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991; 51: 349-353
• 52 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. Thromb Res 1989; 55: 279-284
• 53 Costanini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Occurrence of components of fibrinolysis pathways in situ neoplastic and non-neoplastic human breast tissue. Cancer Res 1991; 51: 354-358
• 54 Donati MB, Gambarcorti-Passerini C, Casali B. et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 26: 6471-6474
• 55 Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemostas 1992; 18: 424-433
• 56 Adany R, Kappelmayer J, Berenyi E, Szegeda A, Fabian E, Muszbek L. Factors of the extrinsic pathway of blood coagulation in tumor associated macrophages. Thromb Haemostas 1989; 62: 850-855
• 57 Adany R, Memes Z, Musbek L. Characterization of factor XIII containing macrophages in lymph nodes with Hodgkin’s disease. Br J Cancer 1987; 55: 421-426
• 58 Muszbek L, Adany R. Intratumoral fibrin stabilization. In: Eicosanoids, Lipid Peroxidation and Cancer. Nigam SK, McBrien DCH, Slater TF. (eds) Springer-Verlag; New York: 1988: 339-349
• 59 Grignani G, Pacciarini L, Ricetti MM, Dionigi P, Jemos V, Zucchella M, Fratino P. Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metastasis 1989; 9: 298-309
• 60 Eche N, Sie P, Jozan S, Courriere P, David JF. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). Thromb Res 1986; 43: 121-127
• 61 Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985; 227: 1059-1061
• 62 Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-5632
• 63 Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985
• 64 Ogawa S, Connolly D, Olander JV, Familetti PC, Stern D, Clauss M. Vascular permeability factor (VPF): A tumor-derived polypeptide which induced endothelial cell and monocyte procoagulant activity and promotes monocyte migration. Thromb Haemostas 1991; 65: 648
• 65 Donati MB, Semeraro N. Cancer cell procoagulants and their pharmacological modulation. Haemostasis 1984; 14: 422-429
• 66 van Dewater L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985; 45: 5521-5525
• 67 Sakai T, Lund-Hansen T, Paborsky L, Pedersen AH, Kisiel W. Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). Implications for the initiation of the extrinsic pathway of blood coagulation. J Biol Chem 1989; 264: 9980-9988
• 68 Sakai T, Kisiel W. Binding of human factors X and Xa to Hep G2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va. J Biol Chem 1990; 265: 9105-9113
• 69 Rickles FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastatic agents. I. The role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemostas 1988; 14: 88-94
• 70 Semeraro N, De Lucia O, Lattanzio A, Montemurro P, Giordano D, Loizzi M, Carpagnano F. Procoagulant activity of human alveolar macrophages. Different expression in patients with lung cancer. Int J Cancer 1986; 37: 525-529
• 71 Semeraro N, Montemurro P, Conese M, Giordano D, Stella M, Restaino A, Cagnazzo G, Colucci M. Procoagulant activity of mononuclear phagocytes from different anatomical sites in gynecologic malignancies. Int J Cancer 1990; 45: 251-254
• 72 Cozzolino F, Torcia M, Miliani A, Carossino AM, Giordani R, Cinotti S, Filimberti E, Saccardi R, Bernabei P, Guidi G, DiGuglielmo R, Pistoia V, Ferrarini M, Nawroth PP, Stern D. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphocytic leukemia. Am J Med 1988; 84: 240-250
• 73 Clariss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Bach R, Familletti PC, Stern D. A polyppetide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem 1990; 265: 7078-7083
• 74 McGee MP, Wallin R, Wheeler FB, Rothberger H. Initiation of the extrensic pathway of coagulation by human and rabbit alveolar macrophages: A kinetic study. Blood 1989; 74: 1583-1590
• 75 Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro NS, Mantovani A, Donati MB. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-273
• 76 Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer: mononuclear cell tissue factor generation. J Lab Clin Med 1981; 98: 917-928
• 77 Morgan D, Edwards RL, Rickles FR. Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients. Haemostasis 1988; 18: 55-65
• 78 Viero P, Cortellazzo S, Caserotto C, Barbui T, Colucci M, Semeraro N. Increased production of mononuclear cell procoagulant activity in Hodgkin’s disease. Eur J Cancer Clin Oncol 1983; 19: 1539-1543
• 79 Osterud B, Due Jr J. Blood coagulation in patients with benign and malignant tumors before and after surgery: special reference to thromboplastin generation in monocytes. Scand J Haematol 1984; 32: 258-264
• 80 Geczy CL, Ryan J, Walsh J, Goldstein D. Lymphokine-induced monocyte procoagulant activity is depressed in patients with advanced malignancies. Int J Cancer 1986; 37: 677-682
• 81 Guarini A, Acero R, Alessio G, Donati MB, Semeraro N, Mantovani A. Procoagulant activity of macrophages associated with different murine neoplasms. Int J Cancer 1984; 34: 581-586
• 82 Lando PA, Edgington TS. An innate host response to the neoplastic cell: syngeneic rat tumor cells can elicit a rapid de novo lymphoid procoagulant response. J Immunol 1985; 125: 3587-3595
• 83 Sharma S, Mehta SR, Ford RJ. Growth factor, viruses, and oncogenes in human lymphoid neoplasia. Lymphokine Res 1987; 6: 245-264
• 84 Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 1987; 126: 506-512
• 85 Mingari MC, Gerosa F, Carra G. et al. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 1984; 312: 2641-2643
• 86 Cordingly FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. Tumour necrosis factor as an autocrine tumor growth factor for chronic B-cell malignancies. Lancet 1988; 1: 969-971
• 87 Hahn T, Kusminsky G, Bassous L, Barak Y, Barrebi A. Tumor necrosis factor in B chronic lymphocytic leukemia. Br J Haematol 1989; 71: 299
• 88 Bennicelli JL, Elias J, Kern J, Guerry D. Production of interleukin-1 activity by cultured human melanoma cells. Cancer Res 1989; 49: 930-935
• 89 Kock A, Schwarz T, Urbanski A, Peng Z, Vitterlein M, Micksche M, Ansel JC, Kung HF, Luger TA. Expression and release of interleukin-1 by different human melanoma cell lines. J Natl Cancer Inst 1989; 81: 36-42
• 90 Sato K, Fujii Y, Kakiuchi T, Kasona K, Imamura H, Kondo Y, Mano H, O-Rabe T, Asano S, Takaku F. Paraneoplastic syndrome of hypercalcemia and leukocytosis caused by squamous carcinoma cells (T3M-1) producing parathyroid hormone-related protein, interleukin 1α, and granulocyte colony-stimulating factor. Cancer Res 1989; 49: 4740-4746
• 91 Ciano PS, Colvin RB, Dvorak AM, McDonagh J, Dvorak HF. Macrophage migration in fibrin gel matrices. Lab Invest 1986; 54: 62-70
• 92 Gorelik E, Bere WW, Herberman RB. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984; 3: 87-94
• 93 Gorelik E. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Cancer Res 1987; 47: 809-815
• 94 Gunji Y, Gorelik E. Role of fibrin coagulation in protection of murine tumor cells from destruction by immune cells. Cancer Res 1988; 48: 5216-5221
• 95 Olander JV, Bremer ME, Marasa JC, Feder J. Fibrin-enhanced endothelial cell organization. J Cell Physiol 1985; 125: 1-9
• 96 Zetter BR, Chen LB, Buchanan JM. Binding and internalization of thrombin by normal and transformed chick cells. Proc Natl Acad Sci 1988; 74: 596-600
• 97 Fair DS, Plow EF. Specific association of thrombin-antithrombin complexes with a human hepatoma cell line. Thromb Res 1986; 41: 67-78
• 98 Maruyama I, Majerus PW. The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells: Endocytosis and degradation of thrombin. J Biol Chem 1985; 260: 15,432-15,438
• 99 Tullis JL, Honegger H, Fleischaker O, Hewitt L, Kenney D, Chao FC. Thrombin inhibition by malignant and normal cells: A cell-bound antithrombin effect. Cancer 1981; 48: 1177-1182
• 100 Carney DH, Stiernberg J, Fenton JW. Initiation of proliferative events by human alpha thrombin. J Cell Biochem 1984; 26: 181-195
• 101 Paris S, Pouyssegur J. Growth factors, activate the Na⁺/K⁺ antiporter in quiescent fibroblasts by increasing its affinity for intracellular H⁺ . J Biol Chem 1984; 259: 10,989-10,994
• 102 Raben DM, Cunningham DD. Effects of EGF and thrombin on inositol-containing phospholipids of cultured fibroblasts: Stimulation of phosphatidylinositol synthesis by thrombin but not EGF. J Cell Physiol 1985; 125: 582-590
• 103 Murayama T, Ui M. Receptor mediated inhibition of adenylate cyclase and stimulation of arachidonic acid release in 3T3 fibroblasts: Selective susceptibility to islet-activating protein, pertusis toxin. J Biol Chem 1985; 260: 7226-7233
• 104 Galdal KS, Lyberg T, Evensen SA, Nilsen E, Prydz H. Thrombin induces thromboplastin synthesis in cultured vascular endothelial cells. Thromb Haemostas 1985; 54: 373-376
• 105 van Obberghen-Schilling E, Chambard JC, Paris S, L’Allemain G, Pouyssegur J. Alpha-thrombin-induced early mitogenic signalling events and Go to S-phase transition of fibroblasts require continual external stimulation. EMBO J 1985; 4: 2927-2932
• 106 Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 1986; 83: 976-980